Arkin Bio Ventures

Arkin Bio Ventures is an Israeli institutional investor focused on early-stage biotech companies developing therapies for unmet medical needs.

Venture Capital Tel Aviv, Israel Est. 2009
Last updated 2026-11-03
Portfolio
3
in our dataset
Rounds participated
4
Rounds led
2
Rounds' value
$73.0M
total disclosed, rounds participated
Stages
Pre-clinical, Early Clinical-Stage

About

Arkin Bio Ventures is the healthcare-focused investment arm of Arkin Capital, an Israeli firm founded in 2009. It specializes in advanced pre-clinical and early clinical-stage biotech companies, with a focus on oncology, immunology, inflammation, and rare diseases. Arkin Bio Ventures manages over $600 million in biotech-focused assets across early and late-stage strategies.

Portfolio · 3

Enlivex
A clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™ for inflammatory diseases and operating a prediction markets treasury.
Led ★ 1 round $5.0M committed Latest: 2024-05
Eleven Therapeutics
Unleashing the power of RNA to create precise, durable therapeutics by combining AI, massively parallel functional assays, and combinatorial chemistry.
1 round $22.0M committed Latest: 2022-08
BioSight
Developer of therapeutics for oncology & hematological disorders.
Led ★ 2 rounds $46.0M committed Latest: 2020-12
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2009